Andrew Schwab
Managing Partner @ 5AM Ventures
San Francisco, United States
Andrew Schwab is a Series A investor at 5AM Ventures in San Francisco focused on Biotechnology and Health Care. Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures.Prior to founding 5AM Ventures in 2002, Mr. Schwab was a Principal at Bay City Capital (BCC). After joining BCC in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx.Prior to joining BCC, Mr.Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities.At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Anaphore, Cleave Biosciences, DVS Sciences, Flexion Therapeutics, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix) and Viveve.Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of the 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 28%
Last updated:
For AI agents: llms.txt
Industries Andrew Schwab invests in
Stages Andrew Schwab invests in
Countries Andrew Schwab invests in
Investment Focus
Industry
- Biotechnology 8 (44%)
- Health Care 6 (33%)
- Therapeutics 5 (28%)
- Biopharma 3 (17%)
- Medical Device 2 (11%)
Stage
- Series A 8 (44%)
- Series B 5 (28%)
- Post-IPO Equity 2 (11%)
- Seed 1 (6%)
- Series C 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CAMP4 Therapeutics
|
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $50M / Post-IPO Equity / Sep 10, 2025 | |
Fellow Health
|
Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M / Series B / Jul 15, 2025 | |
Escient Pharmaceuticals
|
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $120M / Series C / Nov 28, 2022 | |
Novome Biotechnologies
|
Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $43.5M / Series B / Sep 13, 2022 | |
|
Fellow Health
|
Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M / Series A / Aug 01, 2022 | |
|
CAMP4 Therapeutics
|
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $100M / Series B / Jul 20, 2022 | |
|
CAMP4 Therapeutics
|
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $45M / Series A / Jun 15, 2021 | |
|
Escient Pharmaceuticals
|
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $77.5M / Series B / Sep 14, 2020 | |
|
Novome Biotechnologies
|
Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $33M / Series A / Jan 07, 2020 | |
|
Escient Pharmaceuticals
|
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $40M / Series A / May 09, 2018 | |
| See all 18 investments → | |||
Co-Investors
The Column Group
6 deals together
OUP (Osage University Partners)
4 deals together
Alexandria Venture Investments
2 deals together
Alta Partners
2 deals together
Andreessen Horowitz
2 deals together
Astellas Venture Management
2 deals together
About 5AM Ventures
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
5AM Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Kush Parmar
Managing Partner
|
|||
Scott Rocklage
Founding Partner
|
|||
|
Andrew Schwab
Managing Partner
|
|||
Deborah Palestrant
Partner
|
|||
James W. Young
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Andrew Schwab invest in?
Andrew Schwab invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Andrew Schwab last invest?
The most recent investment recorded for Andrew Schwab closed in Sep 2025. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
